Kim Michael S, Day Chris J, Selinger Christina I, Magno Carly L, Stephens Sebastién R J, Morrison Nigel A
School of Medical Science, Griffith University Gold Coast Campus, Queensland, Australia.
J Biol Chem. 2006 Jan 13;281(2):1274-85. doi: 10.1074/jbc.M510156200. Epub 2005 Nov 8.
MCP-1 (monocyte chemotactic protein-1) is a CC chemokine that is induced by receptor activator of NFkappaB ligand (RANKL) in human osteoclasts. In the absence of RANKL, treatment of human peripheral blood mononuclear cells with macrophage colony-stimulating factor and MCP-1 resulted in tartrate-resistant acid phosphatase (TRAP)-positive multinuclear cells that are positive for calcitonin receptor (CTR) and a number of other osteoclast markers, including nuclear factor of activated t cells, cytoplasmic, calcineurin-dependent 1 (NFATc1). Although NFATc1 was strongly induced by MCP-1 and was observed in the nucleus, MCP-1 did not permit the formation of bone-resorbing osteoclasts, although these cells had the typical TRAP(+)/CTR(+) multinuclear phenotype of osteoclasts. Despite a similar appearance to osteoclasts, RANKL treatment was required in order for TRAP(+)/CTR(+) multinuclear cells to develop bone resorption activity. The lack of bone resorption was correlated with a deficiency in expression of certain genes related to bone resorption, such as cathepsin K and MMP9. Furthermore, calcitonin blocked the MCP-1-induced formation of TRAP(+)/CTR(+) multinuclear cells as well as blocking osteoclast bone resorption activity, indicating that calcitonin acts at two stages of osteoclast differentiation. Ablation of NFATc1 in mature osteoclasts did not prevent bone resorption activity, suggesting NFATc1 is involved in cell fusion events and not bone resorption. We propose that the MCP-1-induced TRAP(+)/CTR(+) multinuclear cells represent an arrested stage in osteoclast differentiation, after NFATc1 induction and cellular fusion but prior to the development of bone resorption activity.
单核细胞趋化蛋白-1(MCP-1)是一种CC趋化因子,由人破骨细胞中的核因子κB受体激活剂配体(RANKL)诱导产生。在缺乏RANKL的情况下,用巨噬细胞集落刺激因子和MCP-1处理人外周血单核细胞,会产生抗酒石酸酸性磷酸酶(TRAP)阳性的多核细胞,这些细胞对降钙素受体(CTR)以及包括活化T细胞核因子细胞质钙调神经磷酸酶依赖性1(NFATc1)在内的许多其他破骨细胞标志物呈阳性。尽管NFATc1被MCP-1强烈诱导并在细胞核中观察到,但MCP-1并不允许形成骨吸收破骨细胞,尽管这些细胞具有破骨细胞典型的TRAP(+)/CTR(+)多核表型。尽管与破骨细胞外观相似,但TRAP(+)/CTR(+)多核细胞要发展出骨吸收活性仍需要RANKL处理。骨吸收的缺乏与某些与骨吸收相关基因(如组织蛋白酶K和基质金属蛋白酶9)表达的缺陷相关。此外,降钙素阻断了MCP-1诱导的TRAP(+)/CTR(+)多核细胞的形成以及破骨细胞的骨吸收活性,表明降钙素在破骨细胞分化的两个阶段起作用。在成熟破骨细胞中敲除NFATc1并不能阻止骨吸收活性,这表明NFATc1参与细胞融合事件而非骨吸收。我们提出,MCP-1诱导的TRAP(+)/CTR(+)多核细胞代表破骨细胞分化的一个停滞阶段,发生在NFATc1诱导和细胞融合之后,但在骨吸收活性发展之前。